(via NewsDirect)
Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive after the company received Human Research Ethics Committee (HREC) approval to conduct its ground-breaking MDMA-assisted clinical therapy for patients with Post-Traumatic Stress Disorder (PTSD). The trial, known as EMDMA-001, will be a 12-month, open-label study conducted in partnership with PAX Centre, one of Australia’s leading trauma-focused, multi-disciplinary psychiatric services specialising in the treatment of complex trauma.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases